▁widely ▁elsewhere ▁throughout ▁the ▁world . ▁ ▁Research ▁Dan az ol ▁has ▁been ▁studied ▁in ▁the ▁treatment ▁of ▁breast ▁cancer ▁in ▁women , ▁but ▁produced ▁relatively ▁low ▁response ▁rates ▁of ▁about ▁ 1 5 ▁to ▁ 2 0 %. ▁ ▁Low - d ose ▁dan az ol ▁has ▁been ▁investig ated ▁in ▁the ▁treatment ▁of ▁di ab etic ▁mac ular ▁ed ema ▁in ▁a ▁phase ▁III ▁clin ical ▁trial . ▁ ▁A ▁ 2 0 1 6 ▁phase ▁I / II ▁pros pective ▁study ▁or ally ▁admin ister ed ▁ 8 0 0   m g ▁per ▁day ▁to ▁ 2 7 ▁patients ▁with ▁tel om ere ▁dise ases . ▁The ▁primary ▁effic acy ▁endpoint ▁was ▁a ▁ 2 0 % ▁reduction ▁in ▁the ▁annual ▁rate ▁of ▁tel om ere ▁attr ition ▁measured . ▁To xic ▁effects ▁formed ▁the ▁primary ▁safety ▁endpoint . ▁The ▁study ▁was ▁halt ed ▁early , ▁after ▁tel om ere ▁attr ition ▁was ▁reduced ▁in ▁all ▁ 1 2 ▁patients ▁who ▁could ▁be ▁evaluated . ▁ 1 2 ▁of ▁ 2 7 ▁patients ▁achieved ▁the ▁primary ▁effic acy ▁end ▁point , ▁ 1 1 ▁of ▁whom ▁increased ▁tel om ere ▁length ▁at ▁ 2 4 ▁months . ▁H emat olog ic ▁responses ▁( second ary ▁effic acy ▁endpoint ) ▁occurred ▁in ▁ 1 0 ▁of ▁ 1 2 ▁patients ▁who ▁could ▁be ▁evaluated ▁at ▁ 2 4 ▁months . ▁E lev ated ▁li ver - enz yme ▁levels ▁and ▁mus cle ▁cr amps ▁( known ▁ad verse ▁effects )